85 related articles for article (PubMed ID: 25140975)
1. The metabolic syndrome and DYRK1B.
Morita H; Komuro I
N Engl J Med; 2014 Aug; 371(8):785. PubMed ID: 25140975
[No Abstract] [Full Text] [Related]
2. The metabolic syndrome and DYRK1B.
He JL; Qiao GF; Li BY
N Engl J Med; 2014 Aug; 371(8):785. PubMed ID: 25140974
[No Abstract] [Full Text] [Related]
3. DYRK1B variant linked to autosomal dominant metabolic syndrome.
Hickmott J
Clin Genet; 2015 Jan; 87(1):30-1. PubMed ID: 25092113
[No Abstract] [Full Text] [Related]
4. The metabolic syndrome and DYRK1B.
Mirshahi T; Murray MF; Carey DJ
N Engl J Med; 2014 Aug; 371(8):784-5. PubMed ID: 25140973
[No Abstract] [Full Text] [Related]
5. The metabolic syndrome and DYRK1B.
Keramati AR; Fathzadeh M; Mani A
N Engl J Med; 2014 Aug; 371(8):785-6. PubMed ID: 25140972
[No Abstract] [Full Text] [Related]
6. DYRK1B haploinsufficiency in a family with metabolic syndrome and abnormal cognition.
Orenstein N; Gofin Y; Shomron N; Ruhrman-Shahar N; Magal N; Hagari O; Azulay N; Bazak L; Goldberg Y; Basel-Salmon L
Clin Genet; 2022 Feb; 101(2):265-266. PubMed ID: 34786696
[TBL] [Abstract][Full Text] [Related]
7. Genetics: Founder mutations identified in an inherited form of the metabolic syndrome.
Holmes D
Nat Rev Endocrinol; 2014 Jul; 10(7):377. PubMed ID: 24889900
[No Abstract] [Full Text] [Related]
8. A form of the metabolic syndrome associated with mutations in DYRK1B.
Keramati AR; Fathzadeh M; Go GW; Singh R; Choi M; Faramarzi S; Mane S; Kasaei M; Sarajzadeh-Fard K; Hwa J; Kidd KK; Babaee Bigi MA; Malekzadeh R; Hosseinian A; Babaei M; Lifton RP; Mani A
N Engl J Med; 2014 May; 370(20):1909-1919. PubMed ID: 24827035
[TBL] [Abstract][Full Text] [Related]
9. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
Abu Jhaisha S; Widowati EW; Kii I; Sonamoto R; Knapp S; Papadopoulos C; Becker W
Sci Rep; 2017 Jul; 7(1):6420. PubMed ID: 28743892
[TBL] [Abstract][Full Text] [Related]
10. Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Ashford AL; Dunkley TP; Cockerill M; Rowlinson RA; Baak LM; Gallo R; Balmanno K; Goodwin LM; Ward RA; Lochhead PA; Guichard S; Hudson K; Cook SJ
Cell Mol Life Sci; 2016 Feb; 73(4):883-900. PubMed ID: 26346493
[TBL] [Abstract][Full Text] [Related]
11. Study of DYRK1B gene expression and its association with metabolic syndrome in a small cohort of Egyptians.
Mohamed YA; Hassaneen HM; El-Dessouky MA; Safwat G; Hassan NA; Amr K
Mol Biol Rep; 2021 Jul; 48(7):5497-5502. PubMed ID: 34291393
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of two DYRK1B variants causative of AOMS3.
Detro-Dassen S; Sternberg A; Lehmann SM; Schwandt K; Düsterhöft S; Becker W
Orphanet J Rare Dis; 2024 Jun; 19(1):233. PubMed ID: 38867326
[TBL] [Abstract][Full Text] [Related]
13. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
Leder S; Czajkowska H; Maenz B; De Graaf K; Barthel A; Joost HG; Becker W
Biochem J; 2003 Jun; 372(Pt 3):881-8. PubMed ID: 12633499
[TBL] [Abstract][Full Text] [Related]
14. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.
Kettle JG; Ballard P; Bardelle C; Cockerill M; Colclough N; Critchlow SE; Debreczeni J; Fairley G; Fillery S; Graham MA; Goodwin L; Guichard S; Hudson K; Ward RA; Whittaker D
J Med Chem; 2015 Mar; 58(6):2834-44. PubMed ID: 25738750
[TBL] [Abstract][Full Text] [Related]
16. DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
Singh R; Dhanyamraju PK; Lauth M
Oncotarget; 2017 Jan; 8(1):833-845. PubMed ID: 27903983
[TBL] [Abstract][Full Text] [Related]
17. High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Kim YM; Lee YJ; Park JH; Lee HD; Cheon CK; Kim SY; Hwang JY; Jang JH; Yoo HW
Clin Genet; 2017 Dec; 92(6):594-605. PubMed ID: 28425089
[TBL] [Abstract][Full Text] [Related]
18. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
van Bon BW; Hoischen A; Hehir-Kwa J; de Brouwer AP; Ruivenkamp C; Gijsbers AC; Marcelis CL; de Leeuw N; Veltman JA; Brunner HG; de Vries BB
Clin Genet; 2011 Mar; 79(3):296-9. PubMed ID: 21294719
[No Abstract] [Full Text] [Related]
19. The serine, threonine, and/or tyrosine-specific protein kinases and protein phosphatases of prokaryotic organisms: a family portrait.
Shi L; Potts M; Kennelly PJ
FEMS Microbiol Rev; 1998 Oct; 22(4):229-53. PubMed ID: 9862122
[TBL] [Abstract][Full Text] [Related]
20. Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Leder S; Weber Y; Altafaj X; Estivill X; Joost HG; Becker W
Biochem Biophys Res Commun; 1999 Jan; 254(2):474-9. PubMed ID: 9918863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
